Peerview Internal Medicine Cme/cne/cpe Audio Podcast

Try it Now Firm without compromise. Cancel whenever you want.

Synopsis

PeerView is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

Episodes

  • Hope S. Rugo, MD, FASCO - Biosimilars as Partners in Oncology: Expert Guidance on Understanding and Incorporating Biosimilar Agents in Real-World Car

    "Hope S. Rugo, MD, FASCO - Biosimilars as Partners in Oncology: Expert Guidance on Understanding and Incorporating Biosimilar Agents in Real-World Car"

    18/05/2020 Duration: 01h01min

    Go online to PeerView.com/BBG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a leading expert discusses key concepts in oncology and supportive care biosimilars, including how they are defined, the regulatory approval process for these agents, and an overview of data for biosimilars in the treatment and supportive care of cancer patients. Upon completion of this activity, participants will be able to: Describe the biosimilar manufacturing process and differences between biosimilars and originator biologics used in the oncology setting, Discuss the concepts of biosimilar interchangeability, therapeutic equivalence, and safety in the context of the regulatory process, Cite efficacy evidence on the use of biosimilars in the management of solid tumors, including breast cancer, lung cancer, GI cancers, and others, Integrate biosimilars into oncology management plans in order to increase patient access to effective medications and improve hea

  • Bradley J. Monk, MD, FACS, FACOG - Expert Views on the Evolving Role of PARP Inhibitors in the Treatment of Ovarian Cancer

    Bradley J. Monk, MD, FACS, FACOG - Expert Views on the Evolving Role of PARP Inhibitors in the Treatment of Ovarian Cancer

    15/05/2020 Duration: 34min

    Go online to PeerView.com/BBX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in oncology discuss current evidence and clinical insights on the evolving role of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors in the frontline and recurrent maintenance settings in patients with ovarian cancer. Upon completion of this activity, participants should be better able to: Review the benefits of maintenance therapy on overall patient outcomes in ovarian cancer management, Summarize new evidence on and recent indications for PARP inhibitors as maintenance therapy in the frontline and recurrent advanced ovarian cancer settings, Select appropriate maintenance interventions based on patient and disease characteristics and response to prior therapy in patients with advanced ovarian cancer.

  • Stephen Krieger, MD, FAAN / Clyde E. Markowitz, MD - Navigating the Evolving Management Paradigm Across Multiple Sclerosis Phenotypes in the Age of Potential Prognostic and Predictive Biomarkers

    Stephen Krieger, MD, FAAN / Clyde E. Markowitz, MD - Navigating the Evolving Management Paradigm Across Multiple Sclerosis Phenotypes in the Age of Potential Prognostic and Predictive Biomarkers

    13/05/2020 Duration: 51min

    Go online to PeerView.com/EQK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a live symposium recently held in West Palm Beach, Florida, leading experts on multiple sclerosis (MS) dive into the latest data on approved and emerging therapies for relapsing and progressive forms of MS and offer practical strategies to improve patient management, treatment selection, and outcomes. In addition to exploring the treatment armamentarium for MS, the panel considers the prognostic and predictive utility of serum neurofilament light chain as an emerging biomarker, including how it may affect disease-modifying treatment selection and sequencing. Upon completion of this activity, participants should be better able to: Apply current data on approved and emerging disease-modifying therapies for the treatment of relapsing forms of MS, Employ recent data related to available and investigational therapies for the treatment of progressive forms o

  • Christian T. Ruff, MD, MPH - Making the Connection: A Call to Action Against Undiagnosed Atrial Fibrillation—Improving Detection, Reducing Risk

    Christian T. Ruff, MD, MPH - Making the Connection: A Call to Action Against Undiagnosed Atrial Fibrillation—Improving Detection, Reducing Risk

    08/05/2020 Duration: 35min

    Go online to PeerView.com/NTH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in cardiology discusses best practices for the screening, diagnosis, and treatment of atrial fibrillation to reduce thromboembolic risk. Upon completion of this activity, participants will be able to: Recognize the prevalence of undiagnosed atrial fibrillation (AF) in patients 65 years and older at risk for AF and stroke, Discuss the need for opportunistic and systematic screening for AF among individuals 65 years of age and older and at high risk for AF and stroke, Employ various screening methods routinely in clinical practice to ensure that patients at risk for AF and stroke are diagnosed, Apply guideline recommendations as well as safety, efficacy, and real-world data on non–vitamin K antagonist oral anticoagulants (NOACs) for thromboembolic risk reduction in patients with AF.

  • Sagar Lonial MD, FACP - Changing Perspectives on Multiple Myeloma and ASCT: Clinical Decision-Making, New Evidence, and Expanding Therapeutic Options

    Sagar Lonial MD, FACP - Changing Perspectives on Multiple Myeloma and ASCT: Clinical Decision-Making, New Evidence, and Expanding Therapeutic Options

    06/05/2020 Duration: 51min

    Go online to PeerView.com/JHF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView CME-certified activity, which is based on a live symposium held adjunct to the 2020 Transplantation and Cellular Therapy (TCT) Meetings of ASTCT and CIBMTR, features expert guidance on the rapidly changing clinical landscape in multiple myeloma (MM), grounding the recent changes in myeloma care squarely within the context of current recommendations for transplant-eligible patients. Each scientific session explores new data with next-generation proteasome inhibitors and immunomodulatory agents, established and emerging antibodies, cell-based therapy, and newer intracellularly targeted options for ASCT-eligible populations, and includes clinical “take homes” designed to capture the major implications of the evidence presented. Upon completion of this activity, participants should be better able to: Cite current practice recommendations for transplant eligibility, min

  • Barbara Burtness, MD - Multimodal Head and Neck Cancer Care Meets the Immunotherapy Era: A Look at the Changing Nature of Multidisciplinary Collaboration and Integrated Treatment StrategiesMedia: Enduring Material

    "Barbara Burtness, MD - Multimodal Head and Neck Cancer Care Meets the Immunotherapy Era: A Look at the Changing Nature of Multidisciplinary Collaboration and Integrated Treatment StrategiesMedia: Enduring Material"

    04/05/2020 Duration: 01h04min

    Go online to PeerView.com/QMH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this educational activity, based on a live event developed by PeerView and the Head and Neck Cancer Alliance and held at the 2020 Multidisciplinary Head and Neck Cancers Symposium, a panel of oncology and radiology professionals assess the latest evidence on immune checkpoint blockade as a part of a multipronged management approach to head and neck cancer (HNC). During this activity, the experts also explore several practical issues arising from the integration of immunotherapy into practice, including the selection of immunotherapy as upfront treatment, management of immune-related events, the use of immune-based multimodal therapy, and referral of patients with resectable or locally advanced disease for clinical trials. Upon completion of this activity, participants should be better able to: Cite updated evidence on immune checkpoint inhibitors in squamous cell carcinoma of

  • Richard S. Finn, MD - Developing a Therapeutic Game Plan for the Management of Hepatocellular Carcinoma: Expert Insights From the Patient CaseBook

    Richard S. Finn, MD - Developing a Therapeutic Game Plan for the Management of Hepatocellular Carcinoma: Expert Insights From the Patient CaseBook

    29/04/2020 Duration: 01h25min

    Go online to PeerView.com/BXY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic management of hepatocellular carcinoma (HCC) has significantly evolved in recent years with the approvals of multikinase, antiangiogenic, and checkpoint inhibitors. Moreover, the treatment landscape is poised to broaden as emerging strategies focus on unmet clinical needs (eg, the use of combination regimens with immunotherapy and targeted agents, dual checkpoint inhibition, and systemic treatment in early disease). This PeerView onDemand activity, based on an engaging CaseBook symposium, features a collection of patient case scenarios detailing critical clinical decision points along the HCC disease spectrum, including ideal sequencing of targeted agents and immune checkpoint inhibitors for patients with advanced HCC and optimal timing of transition from locoregional to systemic therapy for those with early-/intermediate-stage HCC. Each CaseBook segment has been

  • Professor Alan Irvine, MD, DSc - Addressing the Global Burden of Atopic Dermatitis: A Roadmap to Improving Diagnosis, Treatment, and Complete Patient Care

    Professor Alan Irvine, MD, DSc - Addressing the Global Burden of Atopic Dermatitis: A Roadmap to Improving Diagnosis, Treatment, and Complete Patient Care

    27/04/2020 Duration: 28min

    Go online to PeerView.com/GVC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in atopic dermatitis discusses how to effectively diagnose and assess atopic dermatitis, common comorbidities, international treatment guidelines, and optimal treatment strategies, including phosphodiesterase-4 and interleukin-4/-13 inhibitors. Upon completion of this activity, participants should be better able to: Recognize the multidimensional burden and unmet needs associated with atopic dermatitis (AD), Employ evidence-based strategies to determine disease impact and guide treatment decisions in individual patients with AD, Assess clinical data on new and emerging treatment options for atopic dermatitis, Develop individualized treatment plans for adults, adolescents, and children with atopic dermatitis based on current recommendations, the safety and efficacy of new and emerging treatment options, comorbidities, and patient quality of life.

  • Michael G. Ison, MD, MS, FIDSA, FAST - Overcoming Challenges in the Treatment of Influenza: Examining the Underuse of Antiviral Therapies and Exploring Novel Approaches

    Michael G. Ison, MD, MS, FIDSA, FAST - Overcoming Challenges in the Treatment of Influenza: Examining the Underuse of Antiviral Therapies and Exploring Novel Approaches

    24/04/2020 Duration: 47min

    Go online to PeerView.com/JFB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in influenza discusses the use of available and emerging antiviral therapies for the treatment of influenza. Upon completion of this activity, participants will be able to: Recognize the underutilization of antiviral treatment in the management of influenza despite recommendations from practice guidelines, Summarize the mechanisms of action, efficacy, safety, tolerability, and dosing of currently available and novel/emerging antiviral agents for the treatment of influenza, Incorporate currently available and novel/emerging antiviral therapies into the treatment of patients with influenza according to the latest clinical evidence and guideline recommendations.

  • Harry P. Erba, MD, PhD/James M. Foran, MD, FRCPC - The Continuing Wave of Innovation in AML: Getting the Most From the Convergence of Novel Therapy and Allogeneic Transplant

    Harry P. Erba, MD, PhD/James M. Foran, MD, FRCPC - The Continuing Wave of Innovation in AML: Getting the Most From the Convergence of Novel Therapy and Allogeneic Transplant

    20/04/2020 Duration: 51min

    Go online to PeerView.com/WRR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent wave of therapeutic innovation in the management of patients with acute myeloid leukemia (AML) has had implications for many different patient populations, including those who are eligible for allogeneic hematopoietic stem cell transplantation (HCT). Most evidence currently supports a management model that includes the use of newer cytotoxic formulations, novel antibodies, and targeted and epigenetic compounds in conjunction with HCT (eg, as newer induction, conditioning, or maintenance strategies). This expert-led activity, based on a live educational MasterClass held during the 2020 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, explores these new developments and provides insights on the evidence that continues to support the integration of recent therapeutic innovations into the management of transplant-eligible AML populations. This program

  • Mitchell S. Cairo, MD - Following the Trail of Evidence in VOD Management: How Modern Risk Assessment, Diagnostic Principles, and Treatment Are Improving Care

    Mitchell S. Cairo, MD - Following the Trail of Evidence in VOD Management: How Modern Risk Assessment, Diagnostic Principles, and Treatment Are Improving Care

    17/04/2020 Duration: 52min

    Go online to PeerView.com/DYW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In PeerView’s latest CME-certified onDemand activity, based on a symposium at the 2020 Transplantation and Cellular Therapy (TCT) Meetings of ASTCT and CIBMTR, experts lead a series of evidence-based “MasterClass” scientific discussions exploring the nuances of VOD risk assessment, diagnosis, and treatment. The experts also share their perspectives on several adult and pediatric patient cases designed to illustrate how clinicians can “follow the evidence” to apply new recommendations for VOD management and overcome the challenges associated with this serious post-transplant complication. Upon completion of this activity, should be better able to: Identify updated risk factors for VOD, modern diagnostic criteria, and clinical markers of disease severity, Confirm a diagnosis of VOD/SOS in adult and pediatric patients, including those presenting with or without organ dysfunction, i

  • Michael E. Wechsler, MD - The Evolving Landscape of Severe Asthma Management: Selecting Patients for Novel Treatment and Improving Adherence

    Michael E. Wechsler, MD - The Evolving Landscape of Severe Asthma Management: Selecting Patients for Novel Treatment and Improving Adherence

    15/04/2020 Duration: 01h05min

    Go online to PeerView.com/MYK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts on severe asthma discuss how to identify and diagnose patients with this condition and how novel treatments are improving patient outcomes. A patient joins the discussion to share his unique experience with severe asthma and how biologic therapy has improved his quality of life. Upon completion of this activity, participants should be better able to: Diagnose and evaluate patients with asthma for symptom severity, disease phenotypes, exacerbation risk, and eligibility for biologic therapy, Employ evidence-based guidelines and the latest clinical data when selecting treatment for patients with severe asthma, Use strategies to communicate effectively with patients about self-management and to improve inhaler technique, adherence, and overall quality of life in patients with severe asthma.

  • Prithviraj Bose, MD / Jeanne M. Palmer, MD - State-of-the-Art Solutions for Myelofibrosis: The Intersection of JAK Inhibitors, Allogeneic Transplant, and Other Strategies for Patient Care

    Prithviraj Bose, MD / Jeanne M. Palmer, MD - State-of-the-Art Solutions for Myelofibrosis: The Intersection of JAK Inhibitors, Allogeneic Transplant, and Other Strategies for Patient Care

    10/04/2020 Duration: 45min

    Go online to PeerView.com/UQB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of experts in the management of myelofibrosis (MF) offers learners an update on the modern diagnostic and risk assessment strategies that have informed a more considered treatment approach to symptomatic disease. An emerging paradigm, in which potentially curative hematopoietic cell transplantation (HCT) is used in conjunction with Janus kinase (JAK) inhibitor therapy, is discussed, along with an expert-led assessment of JAK inhibitor options in development for MF and how these additions to the treatment arsenal will be used alongside standard approaches. For professionals who are looking to pair recent evidence on JAK inhibitors with HCT and other options in the management of MF, this educational event is an essential disease management resource. Upon completion of this activity, participants should be better able to: Identify clinical symptoms and mol

  • Arjun Balar, MD - Advancing Bladder Cancer Care With Novel Therapeutics: Where We Are Headed With Immunotherapy, Targeted, and Antibody Options

    Arjun Balar, MD - Advancing Bladder Cancer Care With Novel Therapeutics: Where We Are Headed With Immunotherapy, Targeted, and Antibody Options

    08/04/2020 Duration: 01h14min

    Go online to PeerView.com/TYB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With the emergence of immunotherapy as an essential component in the treatment armamentarium for bladder cancer, the therapeutic landscape for this disease has undergone significant transformation in recent years. This educational activity features two experts in a lively discussion about this rapidly evolving treatment landscape. These experts review the latest data and ongoing research on immune checkpoint inhibitors, antibody–drug conjugates, and FGFR inhibitors for the treatment of bladder cancer and discuss the management of adverse events associated with novel therapeutics. Upon completion of this activity, participants will be able to: Review the rationale for use of and latest evidence with approved and investigational therapies, including immune checkpoint inhibitors, antibody–drug conjugates, and FGFR inhibitors, throughout the bladder cancer disease continuum, Describ

  • Pablo F. Mora, MD, FACE, CDE - Go Get the Glucagon! Current and Emerging Options for Treating Severe Hypoglycemia

    Pablo F. Mora, MD, FACE, CDE - Go Get the Glucagon! Current and Emerging Options for Treating Severe Hypoglycemia

    06/04/2020 Duration: 33min

    Go online to PeerView.com/CBF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert endocrinologist and certified diabetes educator discusses current and emerging treatment options for severe hypoglycemia. Upon completion of this activity, participants should be better able to: Recognize the role of glucagon for the treatment of severe hypoglycemia in patients with diabetes, Teach individuals outside of the hospital setting how and when to use glucagon to treat severe hypoglycemia, Evaluate the efficacy, safety, and ease of use of current and emerging glucagon rescue treatments for severe hypoglycemia

  • Carlos E. Bueso-Ramos, MD, PhD / Naval Daver, MD - Precision Diagnostics and Modern Therapy in AML: Innovation and Insights for Pathologists on Personalized Medicine and Team-Based Care

    Carlos E. Bueso-Ramos, MD, PhD / Naval Daver, MD - Precision Diagnostics and Modern Therapy in AML: Innovation and Insights for Pathologists on Personalized Medicine and Team-Based Care

    03/04/2020 Duration: 01h19min

    Go online to PeerView.com/AML20Live?Promocode=860 to view the activity, download slides and practice aids, and complete the post-test to earn credit.

  • Michael R. Bishop, MD - Taking the Leap With CAR T: Opportunities for Improving Care and Optimizing Cell Therapy in Hematologic Cancers

    Michael R. Bishop, MD - Taking the Leap With CAR T: Opportunities for Improving Care and Optimizing Cell Therapy in Hematologic Cancers

    01/04/2020 Duration: 47min

    Go online to PeerView.com/EAA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The emergence and recent approval of a novel adoptive immunotherapy—chimeric antigen receptor (CAR) T cell therapy—offers hope for many patients underserved by standard options. Although initial regulatory approvals have occurred in diseases such as ALL and DLBCL, new evidence is suggesting that CAR T cells will play a role in the care of patients with clear medical needs in settings such as CLL and MCL. In this CME-accredited PeerView MasterClass on-demand activity, experts in hematology and oncology dive into the science behind CAR T cells for patients with hematologic malignancies and discuss strategies for appropriately integrating this innovative therapeutic approach into current management protocols. In doing so, the panel discusses evidence for approved CAR T options, offers insights on its future applications in several different hematologic cancers, and assesses its pot

  • Kurt Schalper, MD, PhD - Leveraging Biomarkers to Guide Candidate Selection for Cancer Immunotherapies: Precision is Paramount, Collaboration is Crucial

    Kurt Schalper, MD, PhD - Leveraging Biomarkers to Guide Candidate Selection for Cancer Immunotherapies: Precision is Paramount, Collaboration is Crucial

    01/04/2020 Duration: 01h22min

    Go online to PeerView.com/Precision20?Promocode=860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies are demonstrating remarkable clinical activity in an increasing number of malignancies, and as the immunotherapy arsenal has continued to expand, it has become clear that reliable biomarkers are needed to guide clinical decisions regarding treatment selection and identification of patients who are most likely to benefit from specific agents or immune-based combinations. A number of proven and putative biomarkers have been and continue to be evaluated, including PD-L1 expression, MSI/MMR, and others. Testing for these biomarkers has significant implications for pathology practice. This PeerView Live Seminars and Tumor Board symposium will provide participating pathology professionals with evidence-based and practical expert instruction on biomarker testing in the era of precision cancer immunotherapy. In the Seminars segments, our expert

  • Manish A. Shah , MD - Evidence and Practicalities: Checkpoint Inhibition in Gastrointestinal Cancers—Translating Recent Advances in Gastric, Esophageal, and Colorectal Cancers

    Manish A. Shah , MD - Evidence and Practicalities: Checkpoint Inhibition in Gastrointestinal Cancers—Translating Recent Advances in Gastric, Esophageal, and Colorectal Cancers

    30/03/2020 Duration: 02h31min

    Go online to PeerView.com/BJU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors have become essential components of the treatment arsenal for gastrointestinal (GI) cancers, and ongoing studies are expected to further refine and expand their role. This video features a MasterClass from the 2020 GI Cancers Meeting in San Francisco where top GI specialists assessed the current state of the science and future potential of immunotherapies and combination treatments, and offered practical guidance in the integration and use of immunotherapies in gastric, esophageal, and colorectal cancers. Don’t miss this discussion so you can better navigate the increasingly complex immunotherapy and biomarker landscape. Upon completion of this activity, participants should be better able to: Describe the rationale for the biomarker-guided use of checkpoint inhibitors, including via testing for PD-L1, MMR/MSI status, and others across the spectrum of

  • Johanna C. Bendell, MD - How I Think, How I Treat—Personal Insights on Current Practices and Evolving Standards of Care in Pancreatic Cancer: Expert Perspectives on Implementing State-of-the-Art Care in the Clinic

    Johanna C. Bendell, MD - How I Think, How I Treat—Personal Insights on Current Practices and Evolving Standards of Care in Pancreatic Cancer: Expert Perspectives on Implementing State-of-the-Art Care in the Clinic

    27/03/2020 Duration: 02h43min

    Go online to PeerView.com/QAF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Innovations in the management of pancreatic cancer have increased hope for patients with this aggressive malignancy. New and promising treatment advances include novel chemotherapy platforms, such as gemcitabine/nab-paclitaxel and nanoliposomal irinotecan–based regimens; targeted systemic approaches, including PARP inhibitors, stroma-targeting agents, and immunotherapies; and other novel modalities, such as tumor treating fields. Modern chemotherapy regimens have improved outcomes for patients in the first- and second-line advanced settings, while practice-changing data on targeted strategies continue to emerge, offering more personalized prospective treatment plans. How has the treatment of pancreatic cancer changed in the first- and second-line metastatic settings? What are the roles of mutation testing and PARP inhibitors in the frontline maintenance setting? What novel solut

page 1 from 9